Acetic acids

FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease

Retrieved on: 
Thursday, July 15, 2021
Enzymes, Chemical compounds, Acetic acids, Organic compounds, Isoquinolines, Roxadustat, Hypoxia-inducible factor, Anemias, Myelodysplastic syndrome, HIF prolyl-hydroxylase inhibitor, Procollagen-proline dioxygenase, Chronic kidney disease

Roxadustat, an oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, is the first HIF-PH inhibitor accepted by the FDA for review for the treatment of anemia of CKD.

Key Points: 
  • Roxadustat, an oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, is the first HIF-PH inhibitor accepted by the FDA for review for the treatment of anemia of CKD.
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).
  • The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia of chronic kidney disease (CKD).
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).

Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

Retrieved on: 
Friday, June 25, 2021
Enzymes, Chemical compounds, Acetic acids, Isoquinolines, Roxadustat, Anemias, Myelodysplastic syndrome, Chronic kidney disease, Procollagen-proline dioxygenase, HIF prolyl-hydroxylase inhibitor, Molidustat

Todays positive CHMP opinion marks a significant step in providing patients with a new and important treatment option for anemia associated with CKD, regardless of dialysis status, saidBernhardt G. Zeiher, M.D., Chief Medical Officer, Astellas.

Key Points: 
  • Todays positive CHMP opinion marks a significant step in providing patients with a new and important treatment option for anemia associated with CKD, regardless of dialysis status, saidBernhardt G. Zeiher, M.D., Chief Medical Officer, Astellas.
  • We look forward to the review and assessment by the European Commission which, if positive, would make roxadustat the first HIF-PH inhibitor approved in Europe to treat symptomatic anemia in adult patients with CKD.
  • Roxadustat is also in Phase 3 clinical development for anemia associated with myelodysplastic syndromes (MDS) and Phase 2 for chemotherapy-induced anemia (CIA).
  • The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD).

Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

Retrieved on: 
Friday, June 25, 2021
Chemical compounds, Acetic acids, Organic compounds, Isoquinolines, Roxadustat, Kidney diseases, Chronic kidney disease, Chronic condition, Anemia, HIF prolyl-hydroxylase inhibitor, Molidustat

The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD).

Key Points: 
  • The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD).
  • Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data.
  • Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated.
  • Anemia in Chronic Kidney Disease: National Institute of Diabetes and Digestive and Kidney Disease.

$1+ Billion Global Monochloroacetic Acid Market (2020 to 2028) - Size, Share & Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Monday, June 21, 2021
Chemicals, Plastics, Manufacturing, Chemistry, Chemical substances, Physical sciences, Amino acids, Acetic acids, Antiseptics, Flavors, N-(2-Carboxyethyl)iminodiacetic acid, Chloroacetic acid, Compound annual growth rate

Among the product type segments, the dry powder product segment accounted for the largest revenue share in the global monochloroacetic acid market in 2020.

Key Points: 
  • Among the product type segments, the dry powder product segment accounted for the largest revenue share in the global monochloroacetic acid market in 2020.
  • Europe market is expected to register a robust revenue CAGR during the forecast period.
  • North America market accounted for moderately high revenue share in the global market in 2020, due to growing consumption of monochloroacetic acid for use in various end-use industries including medical, chemical, and agriculture.
  • A robust analysis and estimation of the Monochloroacetic Acid Market with four levels of quality check - in-house database, expert interviews, governmental regulation, and a forecast specifically done through time series analysis
    A holistic competitive landscape of the all the major players in Monochloroacetic Acid Market.

Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021

Retrieved on: 
Thursday, June 3, 2021
Chemistry, Enzymes, Acetic acids, Physical sciences, Transcription factors, Hypoxia-inducible factor, Vadadustat, Procollagen-proline dioxygenase, European Renal Association – European Dialysis and Transplant Association, Hydroxylation, Hypoxia in fish, Ethylenediaminetetraacetic acid

For more information on ERA-EDTA Virtual Congress 2021, visit: https://www.era-edta.org/en/virtualcongress2021/ .

Key Points: 
  • For more information on ERA-EDTA Virtual Congress 2021, visit: https://www.era-edta.org/en/virtualcongress2021/ .
  • Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.
  • For more information, please visit our website at www.akebia.com , which does not form a part of this release.
  • Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)

Retrieved on: 
Friday, May 14, 2021
Enzymes, Life sciences, Biotechnology, Acetic acids, Isoquinolines, Roxadustat, Hypoxia-inducible factor, Hydroxylation, Procollagen-proline dioxygenase, Biopharmaceutical

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nFibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nFibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer.
  • Its most advanced product is roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (\xe2\x80\x9cHIF-PH\xe2\x80\x9d) activity that acts by stimulating the body\xe2\x80\x99s natural pathway for red cell production.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • If you inquire by email please include your mailing address, telephone number and number of shares purchased.\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.\nGlancy Prongay & Murray LLP, Los Angeles\n'

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts FibroGen (FGEN) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel

Retrieved on: 
Saturday, May 8, 2021
Acetic acids, Branches of biology, Isoquinolines, Roxadustat, Growth factors, Erythropoietin, Stratification, Hazard ratio, Medicine, Medical specialties

To support this marketing edge, FibroGen presented data from phase 3 trials purportedly showing roxadustat was safer than EPO, among other at risk populations, in incident dialysis patients.\nBut after the market closed on Apr.

Key Points: 
  • To support this marketing edge, FibroGen presented data from phase 3 trials purportedly showing roxadustat was safer than EPO, among other at risk populations, in incident dialysis patients.\nBut after the market closed on Apr.
  • 6, 2021, FibroGen stunningly admitted to altering stratification factors to make roxadustat\xe2\x80\x99s hazard ratios indicate lower risk relative to EPO.
  • On this news, the Company\xe2\x80\x99s share price fell over 43%, to close at $19.74 per share on Apr.
  • For the latest news visit our newsroom or follow us on Twitter at @classactionlaw .\n'

FibroGen to Report First Quarter 2021 Financial Results

Retrieved on: 
Monday, May 3, 2021
Medical specialties, Blood, Branches of biology, Anemias, Acetic acids, Myelodysplastic syndrome, Roxadustat, Dysplasia

b"SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2021 financial results on Monday, May 10 after the market close.

Key Points: 
  • b"SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2021 financial results on Monday, May 10 after the market close.
  • FibroGen will also conduct a conference call on that day at 5:00 p.m.
  • ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.\nInterested parties may access a live audio webcast of the conference call via the FibroGen website at https://fibrogen.gcs-web.com/events-and-presentations/events .
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).

FIBROGEN SHAREHOLDERS: June 11, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser

Retrieved on: 
Friday, April 30, 2021
Legal, Professional services, Acetic acids, Isoquinolines, Roxadustat, Chronic kidney disease

A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Key Points: 
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
  • Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff.
  • One of its flagship products is roxadustat, a drug used to treat anemia caused by chronic kidney disease (\xe2\x80\x9cCKD\xe2\x80\x9d).
  • In 2019, FibroGen filed its New Drug Application (\xe2\x80\x9cNDA\xe2\x80\x9d) with the U.S. Food and Drug Administration (\xe2\x80\x9cFDA\xe2\x80\x9d) for the approval of roxadustat.

FibroGen to Present at Upcoming Investor Conference

Retrieved on: 
Wednesday, April 28, 2021
Enzymes, Chemical compounds, Acetic acids, Branches of biology, Transcription factors, Isoquinolines, Roxadustat, Hypoxia-inducible factor, Myelodysplastic syndrome, HIF prolyl-hydroxylase inhibitor, Procollagen-proline dioxygenase, CTGF

A replay will be available for approximately 30 days.\nFibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics.

Key Points: 
  • A replay will be available for approximately 30 days.\nFibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics.
  • The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs.
  • The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD).
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).